Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC)

Recent Results in Cancer Research

Volumn 191, Issue , 2013, Pages 157-183

  Burn, John ^a   Mathers, John ^a   Bishop, D Tim ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BUTYRIC ACID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NOVELOSE; PLACEBO; STARCH; SULINDAC; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ADENOMATOUS POLYP; APC GENE; ARTICLE; BLOATING; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COLORECTAL CANCER; COLORECTAL POLYP; DIGESTIVE SYSTEM ULCER; DRUG RESPONSE; DRUG WITHDRAWAL; EPISTAXIS; EUROPE; FACTORIAL DESIGN; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENE; GENE LOSS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK POPULATION; HUMAN; INHERITANCE; MISMATCH REPAIR; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RECTUM; REGISTER; SIGMOID; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

EID: 84867043676     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-30331-9_9     Document Type: Article

References (48)

1. Bodmer WF, Bailey CJ et al (1987) Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328: 614
2. Boland CR, Thibodeau SN et al (1998) The international workshop on microsatellite instability and rer phenotypes in cancer detection and familial predisposition. Cancer Research 58:5248-5257
3. Boland CR, Thibodeau SN et al (1997) The international workshop on microsatellite instability and rer phenotypes in cancer detection and familial predisposition: 1-35
4. Burn J, Bishop DT et al (2011a) A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 4(5):655-665
5. Burn J, Gerdes AM et al (2011b) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial. Lancet 378:2081-2087
6. Burn J, Bishop DT et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the lynch syndrome. N Engl J Med 359(24):2567-2578
7. Burn J, Chapman P et al (1991) The UK Northern Region genetic register for familial adenomatous polyposis coli: Use of age of onset, congenital hypertrophy of the retinal pigment epithelium, and DNA markers in risk calculations. J Med Genet 28:289-296
8. Cassidy A, Bingham SA et al (1994) Starch intake and colorectal cancer risk: An international comparison. Br J Cancer (London) 69:937-942
9. Chan AT, Arber N et al (2011) Aspirin in the chemoprevention of colorectal neoplasia: An overview. Cancer Prev Res (Phila)
10. Clark S (ed) (2009) A guide to cancer genetics in clinical practice, tfm Publishing Ltd
11. Cole BF, Logan RF et al (2009) Aspirin for the chemoprevention of colorectal adenomas: Metaanalysis of the randomized trials. J Natl Cancer Inst 101(4):256-266
12. Cruz-Correa M, Hylind LM et al (2002) Long-term treatment with sulindac in familial adenomatous polyposis: A prospective cohort study. Gastroenterology 122: 641-645
13. Cuzick J, Otto F et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement. Lancet Oncol 10(5):501-507
14. de la Chapelle A (2004) Genetic predisposition to colorectal cancer. Nat Rev Cancer 4(10): 769-780
15. Dunstone GH, Knaggs TWL (1972) Familial cancer of the colon and rectum. J Med Genet 9:451-454
16. Fishel R, Lescoe MK et al (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75(Dec 3): 1027-1038
17. Giardiello FM, Hamilton SR et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316
18. Giardiello FM, Yang VW et al (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. New England J Med 346(14):1054-1059
19. Giovannucci E, Egan KM et al (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333(10):609-614
20. Grubben M, Braak CVD et al (2001) Effect of resistant starch on potential biomarkers for colonic cancer risk in patients with colonic adenomas: A controlled trial. Dig Dis Sci 46(4):750-756
21. Hampel H, Frankel WL et al (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26(35):5783-5788
22. Herrera L, Kakati S et al (1986) Gardner syndrome in a man with an interstitial deletion of 5q. Am J Med Genet 25:473-476
23. Huang K, Gutierrez LP et al (2011) Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: A matched cohort study. Fam Cancer 10(2):303-308
24. Hylla S, Gostner A et al (1998) Effects of resistant starch on the colon in healthy volunteers: Possible implications for cancer prevention. Am J Clin Nutr 67:136-142
25. Jaeger E, Leedham S, Lewis A et al (2012) Hereditary mixed polyposis syndrome is caused by a 40kb upstream duplication that leads to increased and ectopic expression of the BMPantagonist GREM1 Nature Genetics Epub 6 May doi:10.1038/ng2263
26. Jass JR, Walsh MD et al (2002) Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. Eur J Cancer 38(7):858-866
27. Kune GA, Kune S et al (1988) Colorectal cancer risk, chronic illness, operations, medications: Case control results from the Melbourne colorectal cancer study. Cancer Res 48:4399-4404
28. Labayle D, Fischer D et al (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635-639
29. Lichtenstein DR, Wolfe MM (2000) COX-2-Selective NSAIDs. J Am Med Assoc 284(10): 1297-1299
30. Lynch HT, Krush AJ (1971) Cancer family ''G'' revisited: 1895-1970.) Cancer 27: 1505-1511
31. Lynch HT, Smyrk T et al (1995) Hereditary nonpolyposis colorectal cancer and colonic adenomas: Aggressive adenomas? Semin Surg Oncol 11(6):406-410
32. Lynch HT, Thorson AG et al (1995) Rectal cancer after prolonged sulindac chemoprevention. Cancer 75(4): 936-938
33. McIlhatton MA, Tyler J et al (2011) Aspirin and low dose nitric oxide-donating aspirin increase life span in a lynch syndrome mouse model. Cancer Prev Res 4(5):684-693
34. Mills SJ, Mathers JC et al (2001) Colonic crypt cell proliferation state assessed by whole crypt microdissection in sporadic neoplasia and familial adenomatous polyposis. GUT 48:41-46
35. Nugent KP, Farmer KC et al (1993) Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80(12):1618-1619
36. Rothwell PM, Fowkes FG et al (2011) Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 377(9759):31-41
37. Rothwell PM, Wilson M et al (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376(9754):1741-1750
38. Ruschoff J, Wallinger S et al (1998) Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci U S A 95(19):11301-11306
39. Steinbach G, Lynch PM et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New England J Med 342(26):1946-1952
40. Schwitalle Y, Kloor M (2008) Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134:988-997
41. Thun MJ, Namboodiri MM et al (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596
42. Tomlinson IP, Carvajal-Carmona LG et al (2011) Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet 7(6):e1002105
43. Van Munster IP, Tangerman A et al (1994) Effect of resistant starch on colonic fermentation, bile acid metabolism, and mucosal proliferation. Dig Dis Sci 39(4):834-842
44. Vasen HF (2008) Can the identification of high risk groups increase the effectiveness of colon cancer screening programmes? Z Gastroenterol 46(Suppl 1):S41 - S42
45. Vasen HF, Moslein G et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44(6):353-362
46. Williams EA, Coxhead JM et al (2003) Anti-cancer effects of butyrate: Use of micro-array technology to investigate mechanisms. Proc Nutr Soc 62(1):107-115
47. Young G, Leu RL (2004) Resistant starch and colorectal neoplasia. J AOAC Int 87(3):775-786
48. Lynch HT, Thorson AG et al (1995) Rectal cancer after prolonged sulindac chemoprevention. Cancer 75(4): 936-938.